Clinical Obesity最新文献

Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial 利拉鲁肽对肥胖和COPD患者阻塞性睡眠呼吸暂停和健康相关生活质量影响的探索性分析：一项随机对照试验的二次分析

IF 2.1

Clinical Obesity Pub Date : 2026-03-23 DOI: 10.1111/cob.70079

Sofie Krogh Wolsing, Ayse Dudu Altintas Dogan, Claus Bogh Juhl, Søren Hess, Torben Tranborg Jensen, Else-Marie Bladbjerg, Ole Hilberg

{"title":"Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial","authors":"Sofie Krogh Wolsing, Ayse Dudu Altintas Dogan, Claus Bogh Juhl, Søren Hess, Torben Tranborg Jensen, Else-Marie Bladbjerg, Ole Hilberg","doi":"10.1111/cob.70079","DOIUrl":"10.1111/cob.70079","url":null,"abstract":"Obstructive sleep apnea (OSA) is associated with chronic obstructive pulmonary disease (COPD) and obesity, and all three are linked to reduced health-related quality of life (HRQoL). Coexistence of OSA and COPD increases morbidity and mortality compared to each condition alone. Liraglutide, a glucagon-like peptide 1 receptor agonist, may influence respiratory and HRQoL outcomes. In this secondary exploratory analysis of a randomised controlled trial including individuals with overweight or obesity and COPD, we evaluated effects of liraglutide on OSA prevalence and severity, daytime sleepiness (Epworth Sleepiness Scale, ESS), and HRQoL (Short Form-36 version 2, SF-36v2). In a double-blinded randomised controlled trial, 40 participants with overweight or obesity and COPD from two outpatient clinics were randomised to liraglutide (3.0 mg, subcutaneous) or placebo for 40 weeks. Cardiorespiratory monitoring, SF-36v2 and ESS questionnaires were conducted at baseline and end of treatment. OSA was diagnosed in 84% of participants (70% in the liraglutide group and 85% in the placebo group). Compared to placebo, liraglutide significantly reduced OSA severity, with mean baseline-adjusted differences of −9.87 events/h (β 95% CI −19.5; −0.247, p = 0.044) in Apnea–Hypopnea Index and −10.16 events/h (β 95% CI −19.29; −1.03, p = 0.029) in Oxygen Desaturation Index. ESS scores did not change significantly. Significant improvements were observed in the SF-36v2 subdomains General Health Perception and Role Physical. OSA is common among individuals with overweight or obesity and COPD. Forty weeks of liraglutide treatment were associated with reduced OSA severity and improvements in selected HRQoL domains in this population.","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13008477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe Obesity Management in a Large Academic Health System: A Retrospective Evaluation of Metabolic Bariatric Surgery Counselling Practices 大型学术卫生系统中的严重肥胖管理：对代谢减肥手术咨询实践的回顾性评估。

IF 2.1

Clinical Obesity Pub Date : 2026-03-23 DOI: 10.1111/cob.70077

Mustafa Naveed, Elizabeth Gienger, Tonja Locklear, Amy Frazier, Robert Carpenter

{"title":"Severe Obesity Management in a Large Academic Health System: A Retrospective Evaluation of Metabolic Bariatric Surgery Counselling Practices","authors":"Mustafa Naveed, Elizabeth Gienger, Tonja Locklear, Amy Frazier, Robert Carpenter","doi":"10.1111/cob.70077","DOIUrl":"10.1111/cob.70077","url":null,"abstract":"<div>\u0000 \u0000 Metabolic and bariatric surgery (MBS) is an effective treatment for severe obesity but remains substantially underutilized. Limited data exist on outpatient counselling patterns preceding surgical uptake. Using electronic health record data, we conducted a 10-year retrospective cohort study of adults with body mass index ≥ 40 kg/m2. The primary outcome was documentation of the MBS discussion. Secondary outcomes included MBS receipt and demographic factors associated with documented discussion. Among 60 574 eligible patients, only 7.6% had documented MBS discussion. Overall, 1.2% underwent MBS. Surgery occurred in 12.1% of patients with documented discussion compared with 0.3% without discussion. Patients with documented discussion were younger (median, 42 vs. 47 years), had higher BMI (median, 46.8 vs. 42.0 kg/m2), and were more often female. Eligible women were more likely than men to have documented discussion (8.7% vs. 5.5%). Black patients had higher discussion rates than White patients, despite known downstream disparities in MBS utilization. Documented MBS discussion is rare but represents a critical inflection point in surgical uptake. Demographic differences in counselling suggest clinician- and system-level factors influence access before referral, highlighting outpatient counselling as a key target to improve equitable MBS utilization.\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Misconceptions About Obesity and Weight Stigma in Brazilian Healthcare Professionals 巴西医疗保健专业人员对肥胖和体重污名的误解

IF 2.1

Clinical Obesity Pub Date : 2026-03-18 DOI: 10.1111/cob.70074

Paula Victoria Sozza, Eva Penelo, Stuart William Flint, David Sánchez-Carracedo, Sebastião Sousa Almeida, Telma Maria Braga Costa, Maria Fernanda Laus

{"title":"Misconceptions About Obesity and Weight Stigma in Brazilian Healthcare Professionals","authors":"Paula Victoria Sozza, Eva Penelo, Stuart William Flint, David Sánchez-Carracedo, Sebastião Sousa Almeida, Telma Maria Braga Costa, Maria Fernanda Laus","doi":"10.1111/cob.70074","DOIUrl":"10.1111/cob.70074","url":null,"abstract":"People living with obesity (PLWO) frequently experience weight stigma (WS) in healthcare settings, leading to disparities in treatment. Although research shows that healthcare professionals (HCPs) often hold stigmatising views, this issue remains underexplored in Brazil. The objective of this study is to examine WS and beliefs about obesity amongst Brazilian HCPs. Five hundred seven Brazilian HCPs completed a survey assessing sociodemographic data, beliefs about obesity and the Fat Phobia Scale-Short Form (FPS-SF) for assessing WS. Linear regression models analysed the association between these variables. HCPs who are men (p = 0.007) and physicians (p < 0.001) had significantly higher WS. Participants who attributed overeating to physiological dysfunction (p = 0.004) or the food environment (p = 0.020) reported significantly lower WS compared to those who attributed it to emotional eating. Those who attributed weight loss difficulty to genetic or metabolic factors (p < 0.001) had significantly lower WS compared to those that reported lack of motivation or self-discipline. People who reported a belief that there are factors beyond patients' control (p = 0.001), inadequate care by HCP (p = 0.018) or biological mechanisms (p = 0.007) that prevent weight loss reported significantly lower WS compared to HCPs who believe it's the result of a lack of motivation/self-discipline. In conclusion, higher levels of WS were observed in HCPs who are men, physicians and HCPs who attribute the causes and management of obesity to personal responsibility. These findings emphasise the need for interventions to address WS in HCPs and to improve care for PLWO.","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records 使用多站点电子健康记录进行西马鲁肽和生活方式减肥咨询的比较

IF 2.1

Clinical Obesity Pub Date : 2026-03-13 DOI: 10.1111/cob.70076

William J. B. Powell, Diego R. Mazzotti, Stephen D. Herrmann, Ann M. Davis, Bettina Mittendorfer, Jared Bruce, Xing Song, Lemuel R. Waitman

{"title":"Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records","authors":"William J. B. Powell, Diego R. Mazzotti, Stephen D. Herrmann, Ann M. Davis, Bettina Mittendorfer, Jared Bruce, Xing Song, Lemuel R. Waitman","doi":"10.1111/cob.70076","DOIUrl":"10.1111/cob.70076","url":null,"abstract":"<div>\u0000 \u0000 To evaluate the effectiveness of semaglutide compared with lifestyle counselling alone for weight loss in diabetic and non-diabetic patients with obesity. This multi-site, retrospective, observational study uses data from electronic health records which are part of the Greater Plains Collaborative (GPC) in a time-to-event analysis for comparative effectiveness. Participants were adults with obesity receiving semaglutide for a minimum of 16 weeks or lifestyle counselling with at least three sessions within the first 16 weeks. The primary outcome is incidence of 10% or greater reduction in weight from baseline. Of 3927 eligible participants, 615 were prescribed semaglutide and 3312 received lifestyle counselling. Following propensity score matching, each group (diabetic and non-diabetic) consisted of 120 and 495 participants, respectively. Hazard ratios for 10% weight loss were significantly higher from semaglutide for non-diabetic (1.63 [95% CI: 1.32, 2.01; p < 0.001]) and diabetic (2.45 [95% CI: 1.47, 4.09; p < 0.001]) populations. These data from our study suggest that semaglutide therapy compared with lifestyle counselling alone is more effective in achieving at least 10% weight loss. This information may be used to inform clinical practice guidelines and stimulate future research on the long-term effectiveness of various weight loss options for individuals with obesity.\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GLP-1 Receptor Agonists Versus Bariatric Surgery: Effects of Weight Loss and BMI on Subsequent General Surgical Procedures GLP-1受体激动剂与减肥手术：体重减轻和BMI对随后普通外科手术的影响

IF 2.1

Clinical Obesity Pub Date : 2026-03-09 DOI: 10.1111/cob.70075

Shahzaib Zindani, Selamawit Woldesenbet, Abdullah Altaf, Mujtaba Khalil, Zayed Rashid, Jun Kawashima, Areesh Mevawalla, Azza Sarfraz, Sabrena Noria, Bradley Needleman, Timothy M. Pawlik

{"title":"GLP-1 Receptor Agonists Versus Bariatric Surgery: Effects of Weight Loss and BMI on Subsequent General Surgical Procedures","authors":"Shahzaib Zindani, Selamawit Woldesenbet, Abdullah Altaf, Mujtaba Khalil, Zayed Rashid, Jun Kawashima, Areesh Mevawalla, Azza Sarfraz, Sabrena Noria, Bradley Needleman, Timothy M. Pawlik","doi":"10.1111/cob.70075","DOIUrl":"10.1111/cob.70075","url":null,"abstract":"Obesity and T2DM substantially increase postoperative risk, with higher surgical site infections in obesity and up to a 65% increase in overall complications in T2DM. This study assesses the impact of weight loss interventions—metabolic bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonists (GLP-1RA)—on BMI reduction and how that translates to postoperative outcomes in general surgery patients. Patients undergoing general surgery (2016–2024) were identified in the Epic Cosmos database. GLP-1RA or MBS exposure occurred 1–3 years preoperatively (GLP-1RA coverage ≥ 80%). Entropy balancing produced weighted cohorts with similar baseline profiles, followed by multivariable regression models assessing the association between weight loss intervention and BMI change, and the impact of BMI on postoperative outcomes. Overall 9470 individuals underwent a general surgery procedure. Median patient age was 64, with mostly females (60.6%). More patients received GLP-1RA (n = 7823, 82.3%) than MBS (n = 1647, 17.4%). MBS patients had higher initial BMIs (≥ 40: 60.8% vs. 24.5%, p < 0.001). MBS led to greater BMI reduction than GLP-1RA (Mean difference: −9.89, 95% CI: −9.64, −10.34). Higher BMI at time of a general surgical procedure correlated with increased postoperative complications (OR: 1.01, 95% CI: 1.00–1.01) and extended LOS (OR: 1.01, 95% CI: 1.00–1.01). MBS was associated with lower complication odds (OR: 0.87, 95% CI: 0.78–0.98). MBS improved surgical outcomes in patients with obesity and T2DM through greater BMI reduction compared with GLP-1RAs. These findings support the role of preoperative weight loss to mitigate surgical risk; however, evaluating outcomes relative to no intervention remains an important future direction.","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Randomised Feasibility Study Assessing Acute Physiological Responses to Weight Stigma in Women Living With Obesity 一项评估肥胖女性体重耻辱感急性生理反应的随机可行性研究。

IF 2.1

Clinical Obesity Pub Date : 2026-02-15 DOI: 10.1111/cob.70073

Adrian Brown, Jed Wingrove, Stuart W. Flint

{"title":"A Randomised Feasibility Study Assessing Acute Physiological Responses to Weight Stigma in Women Living With Obesity","authors":"Adrian Brown, Jed Wingrove, Stuart W. Flint","doi":"10.1111/cob.70073","DOIUrl":"10.1111/cob.70073","url":null,"abstract":"Experimental evidence indicates that exposure to weight stigma can lead to sustained elevations in cortisol and ambulatory blood pressure. However, little is known about its acute effects on other physiological markers. This study aimed to explore the feasibility of measuring the physiological response of weight stigma, a novel weight stigmatising paradigm and preliminary efficacy signals. In a prospective randomised feasibility study, women living with obesity were assigned to either a weight stigmatising or non-weight stigmatising paradigm (15 min) and physiological response measured from baseline to 120 min. Eighteen women living with obesity were recruited (nine participants in each group; mean age 43.2 years (SD 10.3); body mass index of 45.8 kg/m2 (SD 5.9); 72.2% White ethnicity). Preliminary efficacy showed an observed acute increase in plasma cortisol (26.7 pg/mL, 95% CI −5.5 to 58.9), alongside increased systolic blood pressure (12.7 mmHg, 95% CI 0.6–24.8), self-reported stress (17.4 mm 95% CI 1.6–33.3), appetite (hunger/desire to eat; 16.8 mm, 95% CI 2.0–31.7; 20.9 mm 95% CI 5.1–36.7, respectively), reduction in peptide YY (−11.8 pg/mL 95% CI −21.6 to −2.01) and fullness (−13.9 95% CI −27.6 to −0.3). No differences were found between the intervention and control group in all measured parameters. Furthermore, this study showed that recruitment, randomisation and measuring real-time physiological response was feasible. This is the first feasibility study attempting to comprehensively characterise the acute physiological impact of experiencing weight stigma in people living with obesity in an experimental setting. Future appropriately powered studies are needed to confirm the preliminary efficacy findings.","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12906996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burden of Obesity in India: Need for Policy Changes to Attain Highest Possible Level of Health and Well-Being 印度的肥胖负担：需要改变政策以达到尽可能高的健康和福祉水平。

IF 2.1

Clinical Obesity Pub Date : 2026-02-02 DOI: 10.1111/cob.70072

Sanjay Kalra, Jothydev Kesavadev, Ramen Goel, Muffazal Lakdawala, Vinayak Agrawal, Neena Malhotra, Nitin Kapoor, Neeta Deshpande, Ankush Desai, Viswanathan Mohan, Rajesh Khadgawat, Balram Sharma

{"title":"Burden of Obesity in India: Need for Policy Changes to Attain Highest Possible Level of Health and Well-Being","authors":"Sanjay Kalra, Jothydev Kesavadev, Ramen Goel, Muffazal Lakdawala, Vinayak Agrawal, Neena Malhotra, Nitin Kapoor, Neeta Deshpande, Ankush Desai, Viswanathan Mohan, Rajesh Khadgawat, Balram Sharma","doi":"10.1111/cob.70072","DOIUrl":"10.1111/cob.70072","url":null,"abstract":"The rise in obesity rates in India in the past 3–4 decades is alarming and obesity management needs transformation. A significant barrier is that obesity is often viewed in India as a lifestyle condition rather than a chronic disease, despite broad international recognition of this status.We propose four overall recommendations to drive transformation of obesity management in India:\u0000\u0000 Policy change is needed in India to ensure that obesity is adequately managed, to improve health of the overall population and reduce disease burden and healthcare costs. Standardised treatment guidelines and algorithms will ensure that individuals with obesity receive up-to-date and consistent support. The burden of obesity can only be addressed through acceptance of obesity as a disease and collaboration across healthcare and policy stakeholders, with significant resource commitments at every level.","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 2","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12865255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Class III Obesity as a Presenting Syndrome in Prolactinoma Patients: Insights Into Obesity and Metabolic Dysfunction in This Unique Group III类肥胖作为催乳素瘤患者的表现综合征：这一独特群体的肥胖和代谢功能障碍的见解

IF 2.1

Clinical Obesity Pub Date : 2026-01-21 DOI: 10.1111/cob.70067

Lukas Andereggen, Christoph Schmid, Michael Brändle, Emanuel Christ

{"title":"Class III Obesity as a Presenting Syndrome in Prolactinoma Patients: Insights Into Obesity and Metabolic Dysfunction in This Unique Group","authors":"Lukas Andereggen, Christoph Schmid, Michael Brändle, Emanuel Christ","doi":"10.1111/cob.70067","DOIUrl":"10.1111/cob.70067","url":null,"abstract":"<div>\u0000 \u0000 The occurrence of patients with lactotroph adenoma presenting with class III obesity is extremely rare. This study reports long-term outcomes of such patients treated with transsphenoidal surgery (TSS) or dopamine agonists (DAs) and integrates findings with existing literature to explore prolactin's (PRL) role in obesity pathophysiology. We analysed BMI and metabolic changes and compared findings with published case series. Four patients presented with class III obesity (BMI range, 40.0–43.1 kg/m2). The diagnostic work-up revealed hyperprolactinemia (PRL range, 56.1–4389 μg/L) and hypogonadism in all patients, with sellar MRI indicating a macroadenoma in all but one patient. Over a median follow-up of 31 months (range 24–144), both TSS (n = 2) and DAs (n = 2) effectively controlled hyperprolactinemia and hypogonadism. BMI changes (ΔBMI/year) were −1.4 ± 1.8 kg/m2/year (TSS) and −3.9 ± 3.4 kg/m2/year (DAs), with non-significant metabolic improvements. Analysis of 22 additional cases revealed similar trends. Higher baseline BMI and macroprolactinoma were risk factors for persistent obesity. Early PRL screening in patients with class III obesity, weight loss interventions and long-term hyperprolactinemia management are essential. Both TSS and DAs provide metabolic benefits, highlighting the need for a multidisciplinary approach in diagnosing and managing lactotroph adenomas with obesity.\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to ‘Changes in Eating Behaviour During Treatment With Obesity Medications’ 更正“在使用肥胖药物治疗期间饮食行为的改变”。

IF 2.1

Clinical Obesity Pub Date : 2026-01-20 DOI: 10.1111/cob.70071

引用次数: 0

Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review 微量营养素和营养缺乏与GLP-1受体激动剂治疗相关：叙述性回顾。

IF 2.1

Clinical Obesity Pub Date : 2026-01-19 DOI: 10.1111/cob.70070

Jorge Urbina, Luis Eduardo Salinas-Ruiz, César Valenciano, Benjamin Clapp

{"title":"Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review","authors":"Jorge Urbina, Luis Eduardo Salinas-Ruiz, César Valenciano, Benjamin Clapp","doi":"10.1111/cob.70070","DOIUrl":"10.1111/cob.70070","url":null,"abstract":"<div>\u0000 \u0000 Glucagon-like peptide-1 receptor agonists (GLP-1RA) such as semaglutide, liraglutide and tirzepatide are effective for obesity and type 2 diabetes mellitus (T2DM) but may predispose users to micronutrient deficiencies through appetite suppression, delayed gastric emptying and altered absorption. Given the rapid rise in GLP-1RA use, clarifying their nutritional impact is clinically important. We conducted a structured search of PubMed and the Cochrane Database (January 2019–May 2025) for adult studies evaluating nutritional or micronutrient outcomes during GLP-1RA therapy. Paediatric studies, those lacking nutrient endpoints, and review articles were excluded. Methods followed SANRA and PRISMA-ScR guidance, and data were synthesised descriptively. Six studies met the inclusion criteria, encompassing 480 825 adults. Vitamin D deficiency was the most common abnormality, occurring in 7.5% at 6 months and 13.6% at 12 months. Iron depletion was frequent, with GLP-1RA users demonstrating 26%–30% lower ferritin levels than SGLT2 inhibitor comparators. More than 60% of users consumed below estimated requirements for calcium and iron, and vitamin D intake averaged 20% of recommendations. Protein and calcium insufficiency contributed to lean mass loss, while thiamine and cobalamin deficits increased over time. GLP-1RA therapy is associated with meaningful nutritional deficiencies. Targeted nutritional assessment and individualised laboratory evaluation may be appropriate for patients at increased risk of malnutrition. Findings are mainly derived from observational datasets, and causality between GLP-1RA therapy and nutritional deficiencies cannot be definitively established.\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0